Annual report
6523.TEDINET S100W5A5
Period2024-04-01 → 2025-03-31
Filed2025-06-25
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 154
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥361.6bn | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥353.9bn | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥356.4bn | 2022-04-01 → 2023-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥340.5bn | 2021-04-01 → 2022-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥306.1bn | 2020-04-01 → 2021-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥22.6bn | 2024-04-01 → 2025-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥1.6bn | 2023-04-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥18.8bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | −¥13.2bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥179m | 2022-04-01 → 2023-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥3.0bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥22.8bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥10.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥12.9bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥3.2bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | −¥8.5bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥16.9bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥10.4bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss IFRS |
| Net income | −¥12.9bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥532.5bn | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥564.3bn | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥561.6bn | at 2023-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥591.3bn | at 2022-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥569.3bn | at 2021-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥391.3bn | at 2025-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥425.2bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥141.2bn | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥139.2bn | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥138.8bn | at 2023-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥141.6bn | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥139.5bn | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥138.0bn | at 2023-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥135.4bn | at 2022-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥107.0bn | at 2021-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥39.6bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥47.0bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥60.9bn | at 2023-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥95.2bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥60.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥41.9bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥41.3bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥21.4bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥51.1bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥47.9bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥8.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥21.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥17.5bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥12.5bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥16.3bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥39.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥39.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥40.8bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥7.0bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥20.4bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥83.13 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-102.48 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-25.84 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥-70.78 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥149.07 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥82.58 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥-102.48 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥-25.84 | 2022-04-01 → 2023-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥-70.78 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥143.93 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥1,122.36 | at 2025-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,106.98 | at 2024-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,101.33 | at 2023-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,092.33 | at 2022-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥921.04 | at 2021-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 26.6% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 24.7% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 24.6% | at 2023-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 22.9% | at 2022-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 18.8% | at 2021-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 7.5% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | -9.3% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | -2.4% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | -7.0% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 19.1% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 9,041 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 9,245 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 9,403 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 9,374 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 9,753 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥16.2bn | 2024-04-01 → 2025-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥39.0bn | 2023-04-01 → 2024-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥32.9bn | 2022-04-01 → 2023-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥39.2bn | 2021-04-01 → 2022-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥8.8bn | 2020-04-01 → 2021-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥8.0bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥30.1bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥7.8bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥23.3bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥17.7bn | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥21.0bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥4.1bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥7.9bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥11.1bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥7.9bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥16.4bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥19.3bn | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥19.9bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥132m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥431.1bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥467.1bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥457.3bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥467.3bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥432.7bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥332.4bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥372.3bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥98.7bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥94.8bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥96.7bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥96.8bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥50.6bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥10.2bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥11.5bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥62.39 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥130.25 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥154.96 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥166.62 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.17 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥62.13 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥129.59 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥153.15 | 2022-04-01 → 2023-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥161.08 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥42 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥54 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥72 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥38 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥778.8 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥751.98 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥759.31 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥763.79 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥428.12 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 22.8% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.1% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.8% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.3% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 11.5% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 8.2% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 17.3% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 20.4% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 27.6% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 126,410,072 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 126,244,271 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 125,522,074 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 124,144,242 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 114,831,084 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 176 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 141 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 151 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 175 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 181 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 35
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2025-03-31 | 288 pure |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | ¥3.7bn |
| Reconciling Itemsreconciling | revenue external | 2024-04-01 → 2025-03-31 | ¥3.7bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥7.8bn |
| Diabetes Managementreportable segment | employees | at 2025-03-31 | 1425 pure |
| Diabetes Managementreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥98.7bn |
| Diabetes Managementreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥98.7bn |
| Diabetes Managementreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥13.9bn |
| Diagnostics And Life Sciencesreportable segment | employees | at 2025-03-31 | 3555 pure |
| Diagnostics And Life Sciencesreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥130.9bn |
| Diagnostics And Life Sciencesreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥130.9bn |
| Diagnostics And Life Sciencesreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥7.2bn |
| Healthcare Solutionsreportable segment | employees | at 2025-03-31 | 3773 pure |
| Healthcare Solutionsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥128.3bn |
| Healthcare Solutionsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥128.3bn |
| Healthcare Solutionsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥9.3bn |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥357.9bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥357.9bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥30.4bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | ¥2.4bn |
| Reconciling Itemsreconciling | revenue external | 2023-04-01 → 2024-03-31 | ¥2.4bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥10.6bn |
| Diabetes Managementreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥101.6bn |
| Diabetes Managementreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥101.6bn |
| Diabetes Managementreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥16.0bn |
| Diagnostics And Life Sciencesreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥129.7bn |
| Diagnostics And Life Sciencesreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥129.7bn |
| Diagnostics And Life Sciencesreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥5.6bn |
| Healthcare Solutionsreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥120.3bn |
| Healthcare Solutionsreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥120.3bn |
| Healthcare Solutionsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥9.4bn |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥351.5bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥351.5bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥12.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2025-03-31 | 176 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,961
| Item | Context | Value | Unit |
|---|---|---|---|
| Gross scope2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | Prior1YearDuration_ConsolidatedAccountingGroupMember | 35304 | |
| Gross scope3 greenhouse gas emissions | Prior1YearDuration | 793687 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | 26 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | 67 | |
| Research and development expenses research and development activities | CurrentYearDuration | 10727000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E36976-000DiabetesManagementReportableSegmentMember | 519000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E36976-000HealthcareSolutionsReportableSegmentMember | 2130000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember | 7998000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 11610000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E36976-000DiabetesManagementReportableSegmentMember | 863000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E36976-000HealthcareSolutionsReportableSegmentMember | 6392000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember | 3194000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 126410072 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 126419238 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 126410072 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 126419238 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 12 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 29 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 288 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 140 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 159 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 24556 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 25184 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 57087 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 10660 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 449047 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 578832 | |
| Number of shares held number of units foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 903 | |
| Number of shares held number of units individuals and others | CurrentYearInstant_OrdinaryShareMember | 167057 | |
| Number of shares held number of units total | CurrentYearInstant_OrdinaryShareMember | 1263586 | |
| Number of shares held shares less than one unit | CurrentYearInstant_OrdinaryShareMember | 51472 | |
| Percentage of shareholdings national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Percentage of shareholdings financial institutions | CurrentYearInstant_OrdinaryShareMember | 0.0452 | |
| Percentage of shareholdings financial service providers | CurrentYearInstant_OrdinaryShareMember | 0.0084 | |
| Percentage of shareholdings other corporations | CurrentYearInstant_OrdinaryShareMember | 0.3554 | |
| Percentage of shareholdings foreigners other than individuals | CurrentYearInstant_OrdinaryShareMember | 0.4581 | |
| Percentage of shareholdings foreign individuals | CurrentYearInstant_OrdinaryShareMember | 0.0007 | |
| Percentage of shareholdings individuals and others | CurrentYearInstant_OrdinaryShareMember | 0.1322 | |
| Number of shares held | CurrentYearInstant_No1MajorShareholdersMember | 47994000 | |
| Shareholding ratio | CurrentYearInstant_No1MajorShareholdersMember | 0.3803 | |
| Number of shares held | CurrentYearInstant_No2MajorShareholdersMember | 21870000 | |
| Shareholding ratio | CurrentYearInstant_No2MajorShareholdersMember | 0.1733 | |
| Number of shares held | CurrentYearInstant_No3MajorShareholdersMember | 12297000 | |
| Shareholding ratio | CurrentYearInstant_No3MajorShareholdersMember | 0.0974 | |
| Number of shares held | CurrentYearInstant_No4MajorShareholdersMember | 9766000 | |
| Shareholding ratio | CurrentYearInstant_No4MajorShareholdersMember | 0.0774 | |
| Number of shares held | CurrentYearInstant_No5MajorShareholdersMember | 5714000 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |